新型冠状病毒肺炎对神经系统的影响

doi:10.19871/j.cnki.xfcrbzz.2021.02.018

摘要/Abstract

摘要： 新型冠状病毒肺炎（COVID-19）为新发急性呼吸道传染病,主要表现为呼吸系统症状,但已有许多文献报道了相关的神经系统症状。最常见症状包括头痛和头晕,严重时出现脑血管意外、吉兰-巴雷综合征、急性横贯性脊髓炎和急性脑炎等并发症,最常见外周表现为嗅觉减退。需要注意的是,神经系统症状可先于典型的呼吸道临床表现,导致漏诊。因此,本文就COVID-19对相关神经系统的影响进行综述。

关键词: 新型冠状病毒肺炎, 神经系统, 研究进展

Abstract: Coronavirus disease 2019 (COVID-19) is a new acute respiratory infectious disease, the main manifestations of COVID-19 are respiratory symptoms, but related neurological symptoms have been reported in many literature. The most common symptoms include headache and dizziness, and complications such as cerebrovascular accidents, Guillain-Barre syndrome, acute transmyelitis and acute encephalitis will occur in severe cases, the most common peripheral presentation is hyposmia. It should be note sometimes neurological manifestations may precede the typical clinical manifestations, leading to the possibility of missed diagnosis. Therefore, this paper reviews the effects of COVID-19 on the nervous system.

Key words: Coronavirus disease 2019, Nervous system, Research progress

黄斌, 高波. 新型冠状病毒肺炎对神经系统的影响[J]. 新发传染病电子杂志, 2021, 6(2): 155-159.

Huang Bin, Gao Bo. The impact of COVID-19 on the nervous system[J]. Electronic Journal of Emerging Infectious Diseases, 2021, 6(2): 155-159.

参考文献

[1] LI Q, GUAN X, WU P, et al.Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia[J]. N Engl J Med, 2020, 382(13):1199-1207.
[2] PASCARELLA G, STRUMIA A, PILEOG C, et al.COVID-19 diagnosis and management: a comprehensive review[J]. J Intern Med, 2020, 288(2):192-206.
[3] 李倩,卢洪洲. 新型冠状病毒疫苗研究最新进展[J/CD]. 新发传染病电子杂志, 2020,5(4):60-65.
[4] MAO L, JIN H, Wang M, et al.Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China[J]. JAMA Neurol, 2020, 77(6):683-690.
[5] HELMS J, KREMER S, MERDJI H, et al.Neurologic Features in Severe SARS-CoV-2 Infection[J]. N Engl J Med, 2020, 382(23):2268-2270.
[6] MORIGUCHI T, HARII N, GOTO J, et al.A first case of meningitis/encephalitis associated with SARS-Coronavirus-2[J]. Int J Infect Dis. 2020, 94:55-58.
[7] LECHIEN JR, CHIESA-ESTOMBA CM, DE SIATI DR, et al.Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study[J]. Eur Arch Otorhinolaryngol, 2020, 277(8):2251-2261.
[8] GONZÁLEZ-PINTO T, LUNA-RODRÍGUEZ A, MORENO-ESTÉBANEZ A, et al. Ruiz-Lopez M. Emergency room neurology in times of COVID-19: malignant ischaemic stroke and SARS-CoV-2 infection[J]. Eur J Neurol, 2020, 27(9):e35-e36.
[9] OXLEY TJ, MOCCO J, MAJIDI S, et al.Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young[J]. N Engl J Med, 2020, 382(20):e60.
[10] BEYROUTI R, ADAMS ME, BENJAMIN L, et al.Characteristics of ischaemic stroke associated with COVID-19[J]. J Neurol Neurosurg Psychiatry, 2020, 91(8):889-891.
[11] VIGUIER A, DELAMARRE L, DUPLANTIER J,et al.Acute ischemic stroke complicating common carotid artery thrombosis during a severe COVID-19 infection[J]. J Neuroradiol, 2020, 47(5):393-394.
[12] NETLAND J, MEYERHOLZ DK, MOORE S, et al.Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2[J]. J Virol, 2008, 82(15):7264-7275.
[13] PAYUS AO, LIEW SLC, MOHD NM, et al.SARS-CoV-2 infection of the nervous system: A review of the literature on neurological involvement in novel coronavirus disease-(COVID-19)[J]. Bosn J Basic Med Sci, 2020, 20(3):283-292.
[14] YAN R, ZHANG Y, LI Y, et al.Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2[J]. Science, 2020, 367(6485):1444-1448.
[15] BAIG AM, KHALEEQ A, ALI U,et al.Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms[J]. ACS Chem Neurosci, 2020, 11(7):995-998.
[16] ALLAMKONDU J, JOHN A, WANI WY, et al.SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(10):165889.
[17] GHEBLAWI M, WANG K, VIVEIROS A, et al.Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2[J]. Circ Res, 2020, 126(10):1456-1474.
[18] CHEN ZM, FU JF, SHU Q, et al.Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus[J]. World J Pediatr, 2020, 16(3):240-246.
[19] MEHTA P, MCAUlEY DF, BROWN M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020, 395(10229):1033-1034.
[20] BOHMWALD K, GÁLVEZ NMS, RÍOS M,et al. Neurologic Alterations Due to Respiratory Virus Infections[J]. Front Cell Neurosci, 2018, 12:386.
[21] SAAD M, OMRANI AS, BAIG K, et al.Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia[J]. Int J Infect Dis, 2014, 29:301-306.
[22] MORIGUCHI T, HARII N, GOTO J, et al.A first case of meningitis/encephalitis associated with SARS-Coronavirus-2[J]. Int J Infect Dis, 2020, 94:55-58.
[23] POYIADJI N, SHAHIN G, NOUJAIM D,et al.COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features[J]. Radiology, 2020, 296(2):E119-E120.
[24] REICHARD RR, KASHANI KB, BOIRE NA, et al.Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology[J]. Acta Neuropathol, 2020, 140(1):1-6.
[25] AL-ANI F, CHEHADE S, LAZOLA. Thrombosis risk associated with COVID-19 infection. A scoping review[J]. Thromb Res, 2020, 192:152-160.
[26] MADJID M, SAFAVI-NAEINI P, SOLOMON SD, et al.Potential Effects of Coronaviruses on the Cardiovascular System: A Review[J]. JAMA Cardiol, 2020, 5(7):831-840.
[27] AGHAGOLI G, GALLO MARIN B, KATCHUR NJ, et al.Neurological Involvement in COVID-19 and Potential Mechanisms: A Review[J]. Neurocrit Care, 2020,1-10.
[28] CAROD-ARTAL FJ.Neurological complications of coronavirus and COVID-19[J]. Rev Neurol, 2020, 70(9):311-322.
[29] BERNAT AL, GIAMMATTEI L, ABBRITTI R,et al.Impact of COVID-19 pandemic on subarachnoid hemorrhage[J]. J Neurosurg Sci, 2020, 64(4):409-410.
[30] MAIDENIUC C, MEMON AB.RETRACTED ARTICLE: Acute necrotizing myelitis and acute motor axonal neuropathy in a COVID-19 patient[J]. J Neurol, 2021, 268(2):739.
[31] ABDELHADY M, ELSOTOUHY A, VATTOTH S.Acute Flaccid Myelitis in COVID-19[J]. BJR Case Rep, 2020, 6(3):20200098.
[32] DURRANI M, KUCHARSKI K, SMITH Z,et al.Acute Transverse Myelitis Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Case Report[J]. Clin Pract Cases Emerg Med, 2020, 4(3):344-348.
[33] SARMA D, BILELLO LA.A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection[J]. Clin Pract Cases Emerg Med, 2020, 4(3):321-323.
[34] DENDROU CA, FUGGER L, FRIESE MA.Immunopathology of multiple sclerosis[J]. Nat Rev Immunol, 2015, 15(9):545-558.
[35] HOWARD J, TREVICK S, YOUNGER DS.Epidemiology of Multiple Sclerosis[J]. Neurol Clin, 2016, 34(4):919-939.
[36] YOSHIMURA S, ISOBE N, MATSUSHITA T, et al.Genetic and infectious profiles influence cerebrospinal fluid IgG abnormality in Japanese multiple sclerosis patients[J]. PLoS One, 2014, 9(4):e95367.
[37] WEGE H.Immunopathological aspects of coronavirus infections[J]. Springer Semin Immunopathol, 1995, 17(2-3):133-148.
[38] ARBOUR N, EKANDÉ S, CÔTÉ G, et al. Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E[J]. J Virol, 1999, 73(4):3326-3337.
[39] WILLIS MD, ROBERTSON NP.Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2[J]. J Neurol, 2020, 267(5):1567-1569.
[40] CONFAVREUX C, VUKUSIC S.Age at disability milestones in multiple sclerosis[J]. Brain, 2006, 129(Pt 3):595-605.
[41] VAIRA LA, SALZANO G, DEIANA G, et al.Anosmia and Ageusia: Common Findings in COVID-19 Patients[J]. Laryngoscope, 2020, 130(7):1787.
[42] SEIDEN AM.Postviral olfactory loss[J]. Otolaryngol Clin North Am, 2004, 37(6):1159-1166.
[43] MOEIN ST, HASHEMIAN SM, MANSOURAFSHAR B, et al.Smell dysfunction: a biomarker for COVID-19[J]. Int Forum Allergy Rhinol, 2020, 10(8):944-950.
[44] YAN CH, FARAJI F, PRAJAPATI DP,et al.Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms[J]. Int Forum Allergy Rhinol, 2020, 10(7):806-813.
[45] BAGHERI SH, ASGHARI A, FARHADI M, et al.Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak in Iran[J]. Med J Islam Repub Iran, 2020, 34:62.
[46] LAO WP, IMAM SA, NGUYEN SA.Anosmia, hyposmia, and dysgeusia as indicators for positive SARS-CoV-2 infection[J]. World J Otorhinolaryngol Head Neck Surg, 2020, 6(Suppl 1):S22-S25.
[47] KRAJEWSKA J, KRAJEWSKI W, ZUB K, et al.COVID-19 in otolaryngologist practice: a review of current knowledge[J]. Eur Arch Otorhinolaryngol, 2020, 277(7):1885-1897.
[48] MARTÍN-AGUILAR L, PASCUAL-GOÑI E, QUEROL L. Autoantibodies in immune-mediated inflammatory neuropathies. Autoanticuerpos en neuropatías inflamatorias inmunomediadas[J]. Med Clin (Barc), 2019, 153(9):360-367.
[49] FANTINI J, DI SC, CHAHINIAN H, et al.Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection[J]. Int J Antimicrob Agents, 2020, 55(5):105960.
[50] ZHAO H, SHEN D, ZHOU H, et al.Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?[J]. Lancet Neurol, 2020, 19(5):383-384.
[51] TOSCANO G, PALMERINI F, RAVAGLIA S, et al.Guillain-Barré Syndrome Associated with SARS-CoV-2[J]. N Engl J Med. 2020, 382(26):2574-2576.
[52] 卢亦波, 周静如, 莫移美, 等. 31例新型冠状病毒肺炎临床及CT影像表现初步观察[J/CD]. 新发传染病电子杂志, 2020, 5(2):79-82.